Cole v. Janssen Pharmaceuticals, Inc.

265 F. Supp. 3d 892
CourtDistrict Court, E.D. Wisconsin
DecidedJuly 13, 2017
DocketCase No. 15-CV-57
StatusPublished
Cited by6 cases

This text of 265 F. Supp. 3d 892 (Cole v. Janssen Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Wisconsin primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cole v. Janssen Pharmaceuticals, Inc., 265 F. Supp. 3d 892 (E.D. Wis. 2017).

Opinion

[893]*893ORDER DENYING MOTION FOR RECRUITMENT OF COUNSEL

William C. Griesbach, Chief Judge

On January 16, 2015, Plaintiff Reginald S. Cole, Jr., a prisoner currently serving a sentence in a Wisconsin prison, filed this 42 U.S.C. § 1983 action against a defendant he identified as “Risperdal Manufacturer.” (ECF No. 1.) By way of background, Risperdal is a drug used to treat mental health conditions and is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. According to an online news report, there are currently more than 5,500 lawsuits pending in the Complex Litigation Center of the Philadelphia Court of Common Pleas alleging injuries arising out of the use of Risperdal. The cases generally allege that Risperdal use caused boys and young men to undergo gynecomastia, a condition in which a male develops female breast tissue. As of April 10,, 2017, eight of the cases had gone to trial with verdicts evenly split between defendants and plaintiffs, including a $77 million plaintiff’s verdict in one case. See Philadelphia Flooded With Nets Risperdal Lawsuits; Trials Split But Include Massive Verdict, FORBES, https://www. forbes.com/sitesAegalnewsline/2017/04/10/ philadelphia-flooded-with-new-risperdal-lawsuits-trials-split-but-include-massive-verdict/#28fea6fc6318 (last visited July 11, 2017).

In his ’ complaint, Cole alleged that he had been prescribed Risperdal for mental health issues while in prison and suffered side effects including pain and swelling of his breasts, dizziness, nausea, fatigue, head and stomach pain, breathing difficulties and vomiting blood. Cole claimed he was in need of surgery and requested damages of no less 'than $2.2 billion. (Id. at 4-6.) Construing the complaint as a product liability action against Janssen Pharmaceuticals, the assigned judge screened the complaint, granted Cole’s motion to proceed without prepayment of fees, and allowed the case to proceed, presumably under the court’s diversity jurisdiction, although the state or states of Cole’s and Janssen’s citizenship are not alleged. (ECF No. 22.) Cole filed an amended complaint on May 27, 2015 that named Janssen as the defendant but still failed to allege the respective citizenship of the parties. On September 23, 2015, Janssen filed’ an answer to the amended complaint in which it admitted only its name and that the case was open, denied all other allegations and asserted 54 affirmative defenses. (ECF No. 58.)

The case was reassigned to me on March 15, 2017, and I have requested supplemental filings of the parties to confirm the existence of federal jurisdiction under 28 U.S.C. § 1332. Currently before the court is the plaintiffs motion to reconsider his request for the appointment of counsel. For the reasons set forth below, the motion will be denied. Because the facts of the case present a number of difficulties with the application of this circuit’s law on recruitment of counsel to eases of this nature, however,, and because the court’s decision on this motion may well be dispos-itive of the entire case, the court’s reasoning will be set forth at some length.

BACKGROUND

On June 5, 2017, Cole filed a motion for reconsideration of his motion to appoint counsel. (ECF No. 140.) According to Cole, he needs an attorney to present evidence at trial and help secure certain documents he is unable to obtain, such as his medical records. Cole also states .that -he needs an attorney to adequately respond to the defendant’s pending motion for summary judgment. Specifically, Cole states that he needs to present evidence, help secure certain medical records at $0.15 per page, and obtain sealed records.

[894]*894The record reflects previous efforts by both Cole and the court to obtain counsel to represent him in his lawsuit. Sometime in the Fall of 2013, Cole saw a personal injury law firm’s television commercial stating that persons who took Risperdal and, developed gynecomastia might be entitled to substantial compensation. (ECF No. 134, Def. PFOF ¶ 28.) Cole apparently contacted two law firms that represent plaintiffs in Risperdal litigation, both of whom declined to take his case based on their initial investigation and/or review of records. The first firm notified Cole of its decision in February of 2014 and the second in June of 2015. (ECF No. 43-1 at 2, 3.) At a status conference held by the previously assigned- judge on March 9, 2016, Cole reported that a law firm named “Risperdal Attorney at Law” may, represent him, but a, telephone call placed to the number he provided was, answered by a representative of Kennedy Hodges LLP, a law firm in Houston, Texas, who advised the court the firm had no record showing that, it represented Cole. Shortly thereafter, Attorney Ellen Presby of the Nemer-off Law Firm in Dallas, Texas called in and offered to represent Cole pro bono if Janssen would consent to have the case transferred to California state court where she had another Risperdal case pending. (ECF No. 71.) Janssen declined to consent to transfer the case, but Attorney Presby nevertheless agreed to represent Cole for the limited purpose of obtaining his pharmacy records. (ECF No. 74.)

Attorney Presby obtained Cole’s records and provided a report to the court. (ECF No. 85, 86.) At an October 26, 2016, status conference, Attorney Presby was discharged after she advised the court she could no longer represent him in this litigation. The court noted at-that time that it had put forth its “best efforts”, to find legal counsel for Cole but was unsuccessful. Stating that it was not in any position to assist Cole further, the court suggested he continue to seek counsel on his own. (ECF No. 96 at 3.) •

Shortly after the case'was reassigned to me, Cole filed another motion for appointment of counsel, which I denied without prejudice noting that I would reconsider his request when the defendant filed a dispositive motion. (ECF No. 128.) Janssen filed its motion for summary judgment on May -30, 2017, and on June 5, 2017, Cole filed his motion for reconsideration asking again that the court recruit an attorney to assist him in bringing his case.

In its brief filed in support of its motion for summary judgment, Janssen argues that Cole’s case is fatally flawed for several reasons. First, Janssen contends that Cole’s own medical records show he has never been diagnosed with gynecomastia. According to Janssen, the nurse from the prison Health Services Unit (HSU) who examined Cole for gynecomastia noted the exam was “unremarkable”, there was “no nipple dimpling or discharge” and “no palpable lumps.” (ECF No. 133 at 4-5.) Based on her examination, Nurse Waltz concluded that there was “no objective evidence of gynecomastia or breast abnormality.” Nurse Waltz added that Cole was a “questionable historian,” (Id. at 5.)

As .for the other alleged side-effects that Cole attributes to his ingestion of Risper-dal, Janssen argues that the medical records show Cole complained of most of the same symptoms at times when he was not taking the medication. Again according to Janssen, Cole’s records show he was first prescribed Risperdal in May 2007. The prescription was discontinued two months later, in July 2007, because Cole refused to take the .medication. He was again prescribed Risperdal, in September 2007, but discontinued it in December 2007, again because he- refused to take it on multiple occasions. He was. taking it again.for a

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Smith v. United States
S.D. Texas, 2025
Williams v. Birdyshaw
E.D. Wisconsin, 2023
Lockridge v. Larson
E.D. Wisconsin, 2023
Riley v. Waterman
E.D. Wisconsin, 2023
Acevedo v. Nichols
E.D. Wisconsin, 2022
William Watts v. Mark Kidman
42 F.4th 755 (Seventh Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
265 F. Supp. 3d 892, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cole-v-janssen-pharmaceuticals-inc-wied-2017.